DERM
Journey Medical Corporation
There isn't enough reported data to score DERM yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
DERM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Unavailable | |
| Strong |
DERM's revenue and balance sheet are currently healthy, and its profitability is stable. There isn't enough data to rate its cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DERM PE Valuation
DERM has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 15x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DERM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect DERM to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
DERM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.30 | — |
| Q3 2026 | -$0.18 | +$0.15 |
| Q2 2026 | -$0.22 | +$0.14 |
| Q1 2026 | -$0.37 | $0.00 |
| Q4 2025 | -$0.47 | +$0.25 |
| Q3 2023 | -$0.84 | +$2.61 |
| Q2 2023 | -$2.21 | +$1.83 |
| Q1 2023 | -$2.18 | +$2.73 |
| Q4 2022 | -$1.69 | +$3.11 |
DERM is still losing money, but far less than before: $0.18 per share over the past year, against $4.91 at its worst in early 2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DERM on earnings quality, reporting a profit while its opponent remains loss making.
DERM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19M | +7.6% |
| Q2 2026 | $18.5M | +23% |
| Q1 2026 | $16M | +21% |
| Q4 2025 | $16.1M | +18% |
| Q3 2025 | $17.6M | +21% |
| Q2 2025 | $15M | +1% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $13.6M | -11% |
DERM's revenue is recovering but still below its 2023 peak: $19M last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2.8% | +5.9 points |
| Q2 2026 | 2.5% | +22 points |
| Q1 2026 | -9.3% | +16 points |
| Q4 2025 | -2.8% | -19 points |
| Q3 2025 | -8.7% | +11 points |
| Q2 2025 | -19% | +0.5 points |
| Q1 2025 | -25% | +52 points |
| Q4 2024 | 16% | +30 points |
DERM's operating margin was −2.8% last quarter, up 5.9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over DERM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DERM on profitability, with a higher operating margin.
DERM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.4M | -$1.1M |
| Q2 2026 | -$1.7M | -$792K |
| Q1 2026 | $2.9M | +$5.7M |
| Q3 2023 | $18.7M | +$26M |
| Q2 2023 | $4M | +$7.3M |
| Q1 2023 | -$6M | -774% |
| Q2 2022 | -$3.3M | +$4.1M |
| Q1 2022 | $884K | -35% |
DERM has burned cash in most quarters: −$5M over the past year, against −$2M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over DERM in the latest year-over-year cash flow comparison.
DERM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +575K shares |
| 1 year | +12% | +3.1M shares |
| 3 years | +33% | +7M shares |
| 5 years | +206% | +18.9M shares |
| Available history | -48% | -26.4M shares |
DERM has 28M diluted shares, up 12% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q3 2019 | $163,999 |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over DERM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DERM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | -1.1x | Net Cash |
| Q4 2020 | 0.2x | Very low |
DERM has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
DERM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.0 | Neutral |
| Stochastic | 7.6 | Oversold |
DERM's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DERM PE vs Healthcare Sector
DERM has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DERM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.38 | 18% below |
| 20 week MA | $6.38 | 31% below |
| 50 week MA | $6.65 | 34% below |
| 100 week MA | $6.59 | 33% below |
| 200 week MA | $5.14 | 15% below |
DERM is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over DERM on trend strength, trading above more of its moving averages.
DERM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $9.50 | $5.70 | -40% |
| 2022 | $5.70 | $1.18 | -79% |
| 2023 | $1.18 | $5.76 | +388% |
| 2024 | $5.76 | $4.17 | -28% |
| 2025 | $4.17 | $7.92 | +90% |
| 2026 YTD | $7.92 | $4.39 | -45% |
DERM's yearly returns have swung widely, from +388% in 2023 to −79% in 2022. It's down 45% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over DERM on returns for 2026, with the stronger performance.